
HJLI
Healthcare · Medical Devices · $98.3M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2021
EPS trend, 90 days to now · +2.9% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 11, 2021 | Before the open | -0.34 | -0.28 | +17.6% |
| May 12, 2021 | After the close | -0.34 | -0.48 | -41.2% |
| Mar 31, 2021 | After the close | -0.98 | -7.35 | -650.0% |
| Nov 6, 2020 | After the close | -1.25 | -2.00 | -60.0% |
| Aug 14, 2020 | Time not confirmed | — | -0.08 | — |
| Jun 8, 2020 | Time not confirmed | — | -0.06 | — |
| Mar 18, 2020 | After the close | -3.25 | -3.25 | 0.0% |
| Oct 31, 2019 | After the close | -3.50 | -2.50 | +28.6% |
| Aug 5, 2019 | After the close | — | -3.25 | — |
| Jun 13, 2019 | Time not confirmed | — | -0.13 | — |
| Feb 27, 2019 | Time not confirmed | — | -3.80 | — |
| Nov 28, 2018 | Time not confirmed | — | -3.13 | — |
| Aug 29, 2018 | Time not confirmed | — | -26.43 | — |
Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue-based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It engages in the development and manufacture of bioprosthetic medical devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep…